Progenics Licenses Relistor® to Salix Outside of Japan
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 2 (Table of Contents)
Published: 28 Feb-2011
DOI: 10.3833/pdr.v2011.i2.1438 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Progenics Pharmaceuticals has found a new partner for its opioid-induced constipation (OIC) drug Relistor® (methylnaltrexone bromide) in the form of Salix Pharmaceuticals. Salix receives the global rights to the drug, excluding Japan, in a deal that is potentially worth more than US$350 M to Progenics. Relistor was previously licensed to Wyeth but Progenics regained the rights to the product in late 2009. Salix will assume development and commercialisation responsibility for the drug from April 2011.
Copyright: © IQVIA 2018
RSS